GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicamen Biotech Ltd (NSE:MEDICAMEQ) » Definitions » Debt-to-Revenue

Medicamen Biotech (NSE:MEDICAMEQ) Debt-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Medicamen Biotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Medicamen Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Medicamen Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Medicamen Biotech's annualized Revenue for the quarter that ended in Dec. 2024 was ₹1,806 Mil. Medicamen Biotech's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.


Medicamen Biotech Debt-to-Revenue Historical Data

The historical data trend for Medicamen Biotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicamen Biotech Debt-to-Revenue Chart

Medicamen Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.17 0.22 0.18 0.17

Medicamen Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.16 - 0.11 -

Competitive Comparison of Medicamen Biotech's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicamen Biotech's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicamen Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Medicamen Biotech's Debt-to-Revenue falls into.


;
;

Medicamen Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Medicamen Biotech's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(298.56 + 12.555) / 1793.062
=0.17

Medicamen Biotech's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 1805.688
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Medicamen Biotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medicamen Biotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicamen Biotech Business Description

Traded in Other Exchanges
Address
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, IND, 110019
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. The company generates revenue from the sale of pharmaceutical products.

Medicamen Biotech Headlines

No Headlines